Obesity Medicine

Latest News

Lilly’s Oral GLP-1 Orforglipron Shows Significant A1c and Weight Reductions in Phase 3 Trial / image credit ©MichaelVi/stock.adobe.com
Lilly’s Oral GLP-1 Orforglipron Shows Significant and Competitive A1c and Weight Reductions in Phase 3 Trial

April 17th 2025

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

 Mediterranean Diet Combined with Physical Activity Mitigate Bone Density Decline in Older, At-Risk Women, New Analysis Finds / image credit  Rovira i Virgili University
Mediterranean Diet Combined with Physical Activity Mitigate Bone Density Decline in Older, At-Risk Women, New Analysis Finds

April 15th 2025

FDA, Novo Nordisk Investigating Counterfeit Semaglutide Injection in US Supply Chain / Image credit: ©Natalia/AdobeStock
FDA, Novo Nordisk Investigating Counterfeit Semaglutide Injection in US Supply Chain

April 14th 2025

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

April 11th 2025

Incretin-Based Obesity Medications Show Minimal Lean Muscle Mass Loss in 6-Month Prospective Study / image courtesy of Weight Wellness Medicine
Incretin-Based Obesity Medications Show Minimal Lean Muscle Mass Loss in 6-Month Prospective Study

April 10th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.